Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Syndax Pharmaceuticals, Inc. (SNDX : NSDQ)
 
 • Company Description   
Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States.

Number of Employees: 59

 
 • Price / Volume Information   
Yesterday's Closing Price: $14.66 Daily Weekly Monthly
20 Day Moving Average: 587,450 shares
Shares Outstanding: 56.23 (millions)
Market Capitalization: $824.37 (millions)
Beta: 1.53
52 Week High: $22.71
52 Week Low: $13.27
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -10.72% -2.24%
12 Week -7.33% 4.15%
Year To Date -33.03% -18.18%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
35 GATEHOUSE DRIVE BUILDING D FLOOR 3
-
WALTHAM,MA 02451
USA
ph: 781-419-1400
fax: 781-419-1420
investorrelations@smiledirectclub.com http://www.syndax.com
 
 • General Corporate Information   
Officers
Michael A. Metzger - Chief Executive Officer and Director
Dennis G. Podlesak - Chairman
Michael A. Metzger - President; Chief Operating Officer and Director
Martin H. Huber - Director
Jennifer Jarrett - Director

Peer Information
Syndax Pharmaceuticals, Inc. (CORR.)
Syndax Pharmaceuticals, Inc. (RSPI)
Syndax Pharmaceuticals, Inc. (CGXP)
Syndax Pharmaceuticals, Inc. (BGEN)
Syndax Pharmaceuticals, Inc. (GTBP)
Syndax Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 87164F105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 56.23
Most Recent Split Date: (:1)
Beta: 1.53
Market Capitalization: $824.37 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.69 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.81 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: 43.12
PEG Ratio: -
Price Ratios
Price/Book: 2.15
Price/Cash Flow: 28.27
Price / Sales: 5.90
EPS Growth
vs. Year Ago Period: -16.67%
vs. Previous Quarter: -134.81%
Sales Growth
vs. Year Ago Period: 33,209.47%
vs. Previous Quarter: 922.84%
ROE
03/31/22 - 5.18
12/31/21 - 9.49
09/30/21 - -41.03
ROA
03/31/22 - 4.51
12/31/21 - 8.09
09/30/21 - -33.87
Current Ratio
03/31/22 - 13.75
12/31/21 - 21.68
09/30/21 - 8.30
Quick Ratio
03/31/22 - 13.75
12/31/21 - 21.68
09/30/21 - 8.30
Operating Margin
03/31/22 - -
12/31/21 - 17.84
09/30/21 - -678.57
Net Margin
03/31/22 - -
12/31/21 - 17.84
09/30/21 - -678.57
Pre-Tax Margin
03/31/22 - 11.11
12/31/21 - 17.84
09/30/21 - -678.57
Book Value
03/31/22 - 6.81
12/31/21 - 8.27
09/30/21 - 4.09
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.04
12/31/21 - 0.05
09/30/21 - 0.06
Debt-to-Capital
03/31/22 - 4.21
12/31/21 - 4.65
09/30/21 - 5.23
 

Powered by Zacks Investment Research ©